0001209191-21-023076.txt : 20210325
0001209191-21-023076.hdr.sgml : 20210325
20210325184113
ACCESSION NUMBER: 0001209191-21-023076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210323
FILED AS OF DATE: 20210325
DATE AS OF CHANGE: 20210325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YOUNG JAMES F
CENTRAL INDEX KEY: 0001219864
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 21773949
MAIL ADDRESS:
STREET 1: ONE MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-23
0
0001000694
NOVAVAX INC
NVAX
0001219864
YOUNG JAMES F
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
GAITHERSBURG
MD
20878
1
0
0
0
Common Stock
2021-03-23
4
M
0
10000
46.00
A
20000
D
Common Stock
2021-03-23
4
S
0
4434
227.4324
D
15566
D
Common Stock
2021-03-23
4
S
0
3120
228.4171
D
12446
D
Common Stock
2021-03-23
4
S
0
2446
229.4089
D
10000
D
Common Stock
2021-03-25
4
M
0
10000
27.60
A
20000
D
Common Stock
2021-03-25
4
M
0
37500
3.985
A
57500
D
Common Stock
1500
I
By spouse
Stock Option (Right to Buy)
46.00
2021-03-23
4
M
0
10000
0.00
D
2019-12-13
2028-12-13
Common Stock
10000
0
D
Stock Option (Right to Buy)
27.60
2021-03-25
4
M
0
10000
0.00
D
2018-12-15
2027-12-15
Common Stock
10000
0
D
Stock Option (Right to Buy)
3.985
2021-03-25
4
M
0
37500
0.00
D
2020-12-12
2029-12-12
Common Stock
37500
0
D
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.00 to $227.61, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.00 to $228.89, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.00 to $229.65, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested one (1) year from the December 13, 2018 grant date.
One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 15, 2017 grant date.
One hundred percent (100%) of the shares subject to this option grant under the Plan vested one (1) year from the December 12, 2019 grant date.
/s/ John A. Herrmann III, Attorney-in-Fact
2021-03-25